Expansion into Niche Markets Increases the Number of Microarray Applications Heightening Revenue Opportunities
New analysis from Frost & Sullivan (http://www. healthcare. frost. com), The U. S. DNA Microarrays Markets reveals that DNA microarrays markets earned revenue of $446.8 million in 2005 and estimates to reach $532.1 million in 2012.
Palo Alto, CA (PRWEB) March 5, 2006
The usage of DNA microarray technology continues to expand into niche market areas, such as diagnostics, forensics, environmental sciences, and agriculture. The expansion of microarray technology is expected to dramatically increase the number of experiments conducted resulting in heightened revenues for the total market.
New analysis from Frost & Sullivan (http://www. healthcare. frost. com (http://www. healthcare. frost. com)), The U. S. DNA Microarrays Markets reveals that DNA microarrays markets earned revenue of $446.8 million in 2005 and estimates to reach $532.1 million in 2012.
If interested in a virtual brochure, which provides manufacturers, end users and other industry participants an overview of the latest analysis of the U. S. DNA Microarrays Markets, then send an email to Melina Trevino, Corporate Communications at melina. trevino @ frost. com with your full name, company name, title, telephone number, fax number and email. Upon receipt of the above information, an overview will be sent to you by e-mail.
“The DNA microarray market has experienced a shift from homebrew to commercial microarray method,” notes Frost & Sullivan Industry Manager, Jessica Shah. “Scientists traditionally using homebrew methods are moving towards commercial technology for higher sensitivity results.”
Commercial platforms have been proven dramatically improved over time, whereas home-built platforms have not. According to a study conducted by Oregon Health & Science University (OHSU), reproducibility between platforms and across laboratories was generally poor, but reproducibility between laboratories dramatically increased to acceptable levels when a commercial microarray was used with standardized protocols for labeling the RNA, processing the microarrays, acquiring data and other elements. This new era of technology has moved towards commercial microarray technology because of proven reliability.
The DNA microarrays market has been faced with major challenges including, decreased NIH budgets, decreased research focus in genomics, high costs of products, and barriers in receiving FDA approval. Furthermore, inconsistencies from microarray platform to platform, complicates the task of standardization, which is a key challenge to the entire industry.
“However, one of the most pervasive and difficult problems facing manufacturers of the DNA microarray market is making products that are consistent among the various microarray platforms. Inconsistency of data can come from a variety of sources, including probe length, labeling protocols, etc.,” explains Frost & Sullivan Industry Manager, Jessica Shah. “Thus, manufacturers are spending considerable time and effort cross comparing their products to industry standards, which includes quantitative PCR and other microarray platforms. This standardization of data is an essential part of microarrays becoming diagnostic tools."
To address these complex issues, many extensive, joint efforts among public, private and academic organizations are already underway. The Microarray Gene Expression Data (MGED) group was established to develop a framework for describing information about a DNA microarray experiment. The minimum information about microarray experiment (MIAME) was developed to describe the least amount of information that is needed to enable the interpretation of the results of the experiment unambiguously and potentially to reproduce the experiment. In addition, the microarray quality control project (MAQC) was developed to work with the U. S. Food and Drug Administration to provide quality control tools and develop data analysis guidelines.
Manufacturers in the DNA microarray technology space need to contribute to the community by working together. This would tremendously increase the power of microarray technology to advance biology and medicine enabling multidisciplinary collaborations critical for generating usable data.
The U. S. DNA Microarrays Market is a part of the Drug Discovery Technologies Group, provides an overview and outlook for the market. This study has been segmented into arrays, consumables, instrumentations, and software. This research includes detailed market opportunities and industry trends that have been evaluated following extensive interviews with market participants. Interviews are available to the press.
Frost & Sullivan, a global growth consulting company, has been partnering with clients to support the development of innovative strategies for more than 40 years. The company's industry expertise integrates growth consulting, growth partnership services, and corporate management training to identify and develop opportunities. Frost & Sullivan serves an extensive clientele that includes Global 1000 companies, emerging companies, and the investment community by providing comprehensive industry coverage that reflects a unique global perspective and combines ongoing analysis of markets, technologies, econometrics, and demographics. For more information, visit www. frost. com.
# # #
